Company overview

At Apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases where patients have few or no treatment options available. Our programs across ophthalmology, nephrology, hematology, and neurology are further exploring what is possible by targeting C3. You can view our community guidelines here: Community guidelines: http://bit.ly/476Q8
Founded in 2008
Waltham, Massachusetts, USA
796 employees (44 in marketing)
59% recommend to a friend
39% positive business outlook

Salaries

Typical salary range

$116,800 – $175,200

/ yr

Help build salary transparency at Apellis Pharmaceuticals

Share your compensation anonymously to see full data.

Contribute

People

Headcount trend

Company growth over the last 12 months

Headcount +8.9% year over year

Funding

Total funding

$919.6M

Last raise

$275M

Post IPO Debt, 10 months ago

Funding history

Jun 2025

Post IPO Debt Apellis Pharmaceuticals · $275M

May 2024

Post IPO Debt Apellis Pharmaceuticals · $475M

Apr 2022

Post IPO Equity Apellis Pharmaceuticals · $1.1M

Jan 2020

Post IPO Equity Apellis Pharmaceuticals

Aug 2017

Series E Apellis Pharmaceuticals · $60M

Feb 2016

Series D Apellis Pharmaceuticals · $47M

Audience

Monthly website visitors
27.9K
Month over month-0.1%
Quarter over quarter-13.5%
Top sourceDirect (46.1%)
Ad budget per month$0.0
Average search rank40
Traffic source mix
Direct
46.1%
Search
41.6%
Referral
6.4%
Social
4.5%
Paid referral
1.3%

LinkedIn followers

Follower count and growth

Total followers

91.9K

12-mo growth

+20.2%

Monthly growth

+1.2%

News

Links